Recombinant CCR4 (Mogamulizumab Biosimilar) antibody
-
- Target See all CCR4 (Mogamulizumab Biosimilar) products
- CCR4 (Mogamulizumab Biosimilar)
- Antibody Type
- Recombinant Antibody
- Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Chimeric
-
Conjugate
- This CCR4 (Mogamulizumab Biosimilar) antibody is un-conjugated
-
Application
- Depletion (Dep)
- Purpose
- Anti-CCR4 [KW-0761 (Mogamulizumab)], Rabbit IgG, kappa
- Specificity
- This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.
- Characteristics
-
Original Species of Ab: Human
Original Format of Ab: IgG1
- Purification
- Protein A affinity purified
- Immunogen
- This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
- Clone
- KW-0761
- Isotype
- IgG kappa
-
-
- Application Notes
- The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8 % and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action, in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.
- Comment
-
This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- PBS with 0.02 % Proclin 300.
- Preservative
- ProClin
- Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
-
- Target
- CCR4 (Mogamulizumab Biosimilar)
- Abstract
- CCR4 (Mogamulizumab Biosimilar) Products
- Target Type
- Biosimilar
- Background
- CD194, CKR-4, CCR-4, CCR4, K5-5
- UniProt
- P51679
-